SLN // Silence Therapeutics Plc American Depository Share
ANR <GO> NASDAQ RQD COCKPIT → CIK 0001479615 ↗ Health Care • Biotechnology: Pharmaceutical Preparations
$19.76 ▲ +0.01
(+0.05%)
MKT CAP: $1.23B • VOL: 1.19M
52W L $4 52W H $20
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$17
MEDIAN
$22
MEAN
$23
HIGH
$27
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE SLN TAPE
SLN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $23.91 | $22.72 | 2025-02-14 | $17.98 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $24.90 | $23.32 | 2025-02-06 | $18.57 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $22.53 | $21.74 | 2025-01-29 | $18.97 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $20.16 | — | 2025-01-17 | $19.36 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $17.39 | $18.77 | 2025-01-09 | $17.59 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $23.51 | $20.55 | 2024-12-18 | $17.19 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $19.17 | $19.96 | 2024-12-04 | $18.38 | -4.3% | 48% | C |